Which Treatment Fits Your Needs: A Clinical Comparison
GPhC Registration: Your commitment for Mounjaro V Wegovy Safety
When comparing Mounjaro versus Wegovy, choosing a GPhC registered pharmacy ensures your treatment comes from a fully regulated source. EverydayMeds operates under GPhC registration #9012878, meaning our Leicester-based pharmacy undergoes regular inspections and maintains strict standards for prescription-only medicines. Our registration is publicly searchable on pharmacyregulation.org, providing complete transparency about our regulatory status and operational standards.
Unlike unregulated online suppliers, our GPhC registration ensures that both Mounjaro and Wegovy are sourced through official MHRA-approved channels with full traceability. Every prescription undergoes review by UK-licensed prescribers who understand the clinical differences between tirzepatide and semaglutide mechanisms. Our auditable supply chain means you receive genuine medication with proper cold-chain storage from manufacturer to your door, eliminating risks associated with counterfeit or improperly stored treatments.
Mounjaro V Wegovy Pricing: Transparent Costs With No Hidden Fees
Understanding the cost difference between Mounjaro versus Wegovy helps inform your treatment choice alongside clinical considerations. Wegovy pricing starts with 0.25mg at £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to maintenance dose 2.4mg (£209.99). New customers apply discount code FIRST40 at checkout, whilst returning customers use DOSE25 to reach these final prices with no additional reductions needed.
Our bundle options provide convenient supply continuity rather than individual savings calculations. The Intro Trio (0.25mg, 0.5mg, 1mg) costs £299.99 for your first three months, whilst the Ultimate Stability Trio provides three months of 2.4mg maintenance supply for £649.99. Each bundle includes the same temperature-controlled delivery and clinical support, with Mounjaro pricing available upon consultation approval as it requires different dose escalation protocols than Wegovy.
Clinical Evidence: How Mounjaro V Wegovy Compare in Trials
The STEP trials demonstrated semaglutide's effectiveness in weight management, with STEP 1 showing approximately 15% average weight loss at 68 weeks when used alongside reduced-calorie diet and increased physical activity (Wilding et al., NEJM, 2021). Patients with type 2 diabetes in STEP 2 achieved around 9.6% weight reduction, whilst STEP 3 participants with intensive behavioural therapy reached approximately clinically studied weight loss on average.
Mounjaro's SURMOUNT trials evaluated tirzepatide's dual GIP/GLP-1 mechanism in separate study populations with different methodologies, making direct percentage comparisons inappropriate. Both treatments demonstrated significant weight management benefits in their respective clinical programmes, though individual responses vary considerably and depend on adherence to prescribed lifestyle modifications alongside medication.
How Wegovy Works Compared to Mounjaro's Dual Mechanism
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural incretin hormones to reduce appetite and promote satiety after smaller meals. This mechanism works primarily on brain appetite centres, helping decrease food cravings and extending the feeling of fullness between meals. Mounjaro utilises tirzepatide, which targets both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors simultaneously, creating a dual agonist effect. This broader mechanism may influence both appetite regulation and glucose metabolism through complementary pathways. Both treatments require once-weekly injection and work most effectively alongside reduced-calorie diet and increased physical activity rather than as standalone solutions.
Streamlined Ordering Process for Both Mounjaro V Wegovy Options
Our clinical assessment takes approximately three minutes to complete online, covering medical history, current medications, and weight management goals relevant to both Mounjaro and Wegovy consideration. UK-licensed prescribers review your consultation within three working days (24-hour express service available), determining which treatment aligns with your clinical profile and preferences. Once approved, your prescription-only medicine ships via next-day delivery using temperature-controlled packaging that maintains the 2-8°C cold chain from our Leicester pharmacy to your address. Each delivery includes dosing instructions, injection technique guidance, and access to ongoing clinical support throughout your treatment journey with either semaglutide or tirzepatide therapy.
Storage Requirements: Wegovy's Temperature Advantage Over Mounjaro
Both Mounjaro and Wegovy require refrigerated storage at 2-8°C before first use, but Wegovy offers superior travel flexibility with six weeks room temperature tolerance below 30°C once removed from the fridge. Mounjaro provides only 21 days at room temperature, making Wegovy more practical for extended travel or temporary storage situations. Both treatments use pre-filled FlexTouch pens for once-weekly injection, following specific dose escalation schedules that cannot be skipped or accelerated. Wegovy escalates from 0.25mg through 0.5mg, 1mg, 1.7mg to 2.4mg maintenance over 16 weeks, whilst Mounjaro follows its own titration protocol starting from 2.5mg with different progression steps.
Regulatory Compliance: Why GPhC Registration Matters for Mounjaro V Wegovy
Choosing between Mounjaro versus Wegovy through a GPhC registered pharmacy ensures both treatments meet identical regulatory standards for prescription-only medicine handling and distribution. Our registration #9012878 requires annual renewal, regular inspections, and compliance with MHRA guidelines for controlled drug storage and dispensing. This regulatory oversight protects patients from counterfeit medications, improper storage conditions, and unqualified prescribing that can occur with unregistered online suppliers.
Every aspect of our Mounjaro and Wegovy supply chain maintains audit trails from manufacturer receipt through patient delivery, ensuring complete traceability if any safety concerns arise. Our Leicester-based premises undergo regular GPhC inspections, whilst our prescribers hold current GMC registration with specialisation in weight management therapies, providing the clinical expertise necessary for safe tirzepatide and semaglutide prescribing.
Making Your Choice: Expert Support for Mounjaro V Wegovy Decisions
Both Mounjaro and Wegovy are available through EverydayMeds with identical clinical support standards, cold-chain delivery, and ongoing prescriber access throughout your treatment. Your consultation will explore factors like travel requirements (favouring Wegovy's longer room temperature tolerance), injection preferences, previous GLP-1 experience, and individual response expectations to help determine the most suitable option. Remember that both treatments work alongside lifestyle modifications rather than replacing diet and exercise commitments, with individual results varying significantly between patients. Start your clinical assessment today using discount code FIRST40 for new customers at https://everydaymeds.co.uk/collections/wegovy, where UK-licensed prescribers can help determine whether Mounjaro or Wegovy aligns best with your weight management goals and clinical profile.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
